Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
29
CHRS Quote, Financials, Valuation and Earnings
Last price:
$1.21
Seasonality move
:
0.05%
Day range:
$1.18 - $1.27
52-week range:
$0.71 - $1.89
Dividend yield:
0%
P/E ratio:
1.06x
P/S ratio:
1.66x
P/B ratio:
1.65x
Volume:
1M
Avg. volume:
1.3M
1-year change:
-20.53%
Market cap:
$145M
Revenue:
$267M
EPS (TTM):
-$1.59
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CHRS
Coherus Oncology, Inc.
|
$13.4M | -$0.29 | -73.33% | -29.42% | $5.67 |
|
ARMP
Armata Pharmaceuticals, Inc.
|
$1.4M | -$0.42 | 19.84% | -177.23% | $9.00 |
|
AVXL
Anavex Life Sciences Corp.
|
-- | -$0.15 | -- | -22.97% | $22.00 |
|
CRMD
CorMedix, Inc.
|
$86M | $0.63 | 308.6% | 219.78% | $19.00 |
|
MNOV
MediciNova, Inc.
|
-- | -$0.12 | -100% | -109.06% | $7.00 |
|
VSTM
Verastem, Inc.
|
$16.6M | -$0.54 | -88.84% | -63.78% | $16.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CHRS
Coherus Oncology, Inc.
|
$1.20 | $5.67 | $145M | 1.06x | $0.00 | 0% | 1.66x |
|
ARMP
Armata Pharmaceuticals, Inc.
|
$5.63 | $9.00 | $204.5M | -- | $0.00 | 0% | 46.70x |
|
AVXL
Anavex Life Sciences Corp.
|
$4.40 | $22.00 | $393.1M | -- | $0.00 | 0% | -- |
|
CRMD
CorMedix, Inc.
|
$10.56 | $19.00 | $832M | 5.14x | $0.00 | 0% | 3.56x |
|
MNOV
MediciNova, Inc.
|
$1.56 | $7.00 | $76.5M | -- | $0.00 | 0% | 296.67x |
|
VSTM
Verastem, Inc.
|
$10.36 | $16.00 | $780.3M | -- | $0.00 | 0% | 48.41x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CHRS
Coherus Oncology, Inc.
|
38.23% | 0.832 | 28.5% | 0.54x |
|
ARMP
Armata Pharmaceuticals, Inc.
|
216.44% | 3.715 | 164.57% | 0.11x |
|
AVXL
Anavex Life Sciences Corp.
|
-- | -0.800 | -- | 11.47x |
|
CRMD
CorMedix, Inc.
|
1.16% | 3.481 | 0.48% | 1.60x |
|
MNOV
MediciNova, Inc.
|
0.58% | 0.575 | 0.41% | 9.76x |
|
VSTM
Verastem, Inc.
|
121% | -1.113 | 15.18% | 2.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CHRS
Coherus Oncology, Inc.
|
$6.9M | -$42.2M | -115.69% | -- | -364.99% | -$46.3M |
|
ARMP
Armata Pharmaceuticals, Inc.
|
$789K | -$7.8M | -57.86% | -- | -670.92% | -$4.5M |
|
AVXL
Anavex Life Sciences Corp.
|
-- | -$10.8M | -44.87% | -44.87% | -- | -$8.6M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
MNOV
MediciNova, Inc.
|
-$39K | -$3.4M | -24.01% | -24.18% | -2742.09% | -$1.7M |
|
VSTM
Verastem, Inc.
|
$9.3M | -$40.7M | -369.69% | -1773.4% | -362.17% | -$44.5M |
Coherus Oncology, Inc. vs. Competitors
-
Which has Higher Returns CHRS or ARMP?
Armata Pharmaceuticals, Inc. has a net margin of -384.73% compared to Coherus Oncology, Inc.'s net margin of -2301.55%. Coherus Oncology, Inc.'s return on equity of -- beat Armata Pharmaceuticals, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CHRSCoherus Oncology, Inc.59.49% -$0.30 $142.1M ARMPArmata Pharmaceuticals, Inc.68.08% -$0.74 $82.1M -
What do Analysts Say About CHRS or ARMP?
Coherus Oncology, Inc. has a consensus price target of $5.67, signalling upside risk potential of 372.22%. On the other hand Armata Pharmaceuticals, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 59.86%. Given that Coherus Oncology, Inc. has higher upside potential than Armata Pharmaceuticals, Inc., analysts believe Coherus Oncology, Inc. is more attractive than Armata Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CHRSCoherus Oncology, Inc.2 1 0 ARMPArmata Pharmaceuticals, Inc.1 0 0 -
Is CHRS or ARMP More Risky?
Coherus Oncology, Inc. has a beta of 0.951, which suggesting that the stock is 4.926% less volatile than S&P 500. In comparison Armata Pharmaceuticals, Inc. has a beta of 1.240, suggesting its more volatile than the S&P 500 by 23.97%.
-
Which is a Better Dividend Stock CHRS or ARMP?
Coherus Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Coherus Oncology, Inc. pays -- of its earnings as a dividend. Armata Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CHRS or ARMP?
Coherus Oncology, Inc. quarterly revenues are $11.6M, which are larger than Armata Pharmaceuticals, Inc. quarterly revenues of $1.2M. Coherus Oncology, Inc.'s net income of -$44.5M is lower than Armata Pharmaceuticals, Inc.'s net income of -$26.7M. Notably, Coherus Oncology, Inc.'s price-to-earnings ratio is 1.06x while Armata Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Coherus Oncology, Inc. is 1.66x versus 46.70x for Armata Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHRSCoherus Oncology, Inc.1.66x 1.06x $11.6M -$44.5M ARMPArmata Pharmaceuticals, Inc.46.70x -- $1.2M -$26.7M
-
Which has Higher Returns CHRS or AVXL?
Anavex Life Sciences Corp. has a net margin of -384.73% compared to Coherus Oncology, Inc.'s net margin of --. Coherus Oncology, Inc.'s return on equity of -- beat Anavex Life Sciences Corp.'s return on equity of -44.87%.
Company Gross Margin Earnings Per Share Invested Capital CHRSCoherus Oncology, Inc.59.49% -$0.30 $142.1M AVXLAnavex Life Sciences Corp.-- -$0.11 $94.9M -
What do Analysts Say About CHRS or AVXL?
Coherus Oncology, Inc. has a consensus price target of $5.67, signalling upside risk potential of 372.22%. On the other hand Anavex Life Sciences Corp. has an analysts' consensus of $22.00 which suggests that it could grow by 400%. Given that Anavex Life Sciences Corp. has higher upside potential than Coherus Oncology, Inc., analysts believe Anavex Life Sciences Corp. is more attractive than Coherus Oncology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CHRSCoherus Oncology, Inc.2 1 0 AVXLAnavex Life Sciences Corp.2 1 0 -
Is CHRS or AVXL More Risky?
Coherus Oncology, Inc. has a beta of 0.951, which suggesting that the stock is 4.926% less volatile than S&P 500. In comparison Anavex Life Sciences Corp. has a beta of 1.155, suggesting its more volatile than the S&P 500 by 15.531%.
-
Which is a Better Dividend Stock CHRS or AVXL?
Coherus Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Anavex Life Sciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Coherus Oncology, Inc. pays -- of its earnings as a dividend. Anavex Life Sciences Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CHRS or AVXL?
Coherus Oncology, Inc. quarterly revenues are $11.6M, which are larger than Anavex Life Sciences Corp. quarterly revenues of --. Coherus Oncology, Inc.'s net income of -$44.5M is lower than Anavex Life Sciences Corp.'s net income of -$9.8M. Notably, Coherus Oncology, Inc.'s price-to-earnings ratio is 1.06x while Anavex Life Sciences Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Coherus Oncology, Inc. is 1.66x versus -- for Anavex Life Sciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHRSCoherus Oncology, Inc.1.66x 1.06x $11.6M -$44.5M AVXLAnavex Life Sciences Corp.-- -- -- -$9.8M
-
Which has Higher Returns CHRS or CRMD?
CorMedix, Inc. has a net margin of -384.73% compared to Coherus Oncology, Inc.'s net margin of 49.9%. Coherus Oncology, Inc.'s return on equity of -- beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital CHRSCoherus Oncology, Inc.59.49% -$0.30 $142.1M CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About CHRS or CRMD?
Coherus Oncology, Inc. has a consensus price target of $5.67, signalling upside risk potential of 372.22%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 79.92%. Given that Coherus Oncology, Inc. has higher upside potential than CorMedix, Inc., analysts believe Coherus Oncology, Inc. is more attractive than CorMedix, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CHRSCoherus Oncology, Inc.2 1 0 CRMDCorMedix, Inc.4 0 0 -
Is CHRS or CRMD More Risky?
Coherus Oncology, Inc. has a beta of 0.951, which suggesting that the stock is 4.926% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.
-
Which is a Better Dividend Stock CHRS or CRMD?
Coherus Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Coherus Oncology, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CHRS or CRMD?
Coherus Oncology, Inc. quarterly revenues are $11.6M, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Coherus Oncology, Inc.'s net income of -$44.5M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Coherus Oncology, Inc.'s price-to-earnings ratio is 1.06x while CorMedix, Inc.'s PE ratio is 5.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Coherus Oncology, Inc. is 1.66x versus 3.56x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHRSCoherus Oncology, Inc.1.66x 1.06x $11.6M -$44.5M CRMDCorMedix, Inc.3.56x 5.14x $104.3M $108.6M
-
Which has Higher Returns CHRS or MNOV?
MediciNova, Inc. has a net margin of -384.73% compared to Coherus Oncology, Inc.'s net margin of -2473.97%. Coherus Oncology, Inc.'s return on equity of -- beat MediciNova, Inc.'s return on equity of -24.18%.
Company Gross Margin Earnings Per Share Invested Capital CHRSCoherus Oncology, Inc.59.49% -$0.30 $142.1M MNOVMediciNova, Inc.-31.63% -$0.06 $44.2M -
What do Analysts Say About CHRS or MNOV?
Coherus Oncology, Inc. has a consensus price target of $5.67, signalling upside risk potential of 372.22%. On the other hand MediciNova, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 348.72%. Given that Coherus Oncology, Inc. has higher upside potential than MediciNova, Inc., analysts believe Coherus Oncology, Inc. is more attractive than MediciNova, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CHRSCoherus Oncology, Inc.2 1 0 MNOVMediciNova, Inc.2 0 0 -
Is CHRS or MNOV More Risky?
Coherus Oncology, Inc. has a beta of 0.951, which suggesting that the stock is 4.926% less volatile than S&P 500. In comparison MediciNova, Inc. has a beta of 0.483, suggesting its less volatile than the S&P 500 by 51.674%.
-
Which is a Better Dividend Stock CHRS or MNOV?
Coherus Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MediciNova, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Coherus Oncology, Inc. pays -- of its earnings as a dividend. MediciNova, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CHRS or MNOV?
Coherus Oncology, Inc. quarterly revenues are $11.6M, which are larger than MediciNova, Inc. quarterly revenues of $123.3K. Coherus Oncology, Inc.'s net income of -$44.5M is lower than MediciNova, Inc.'s net income of -$3.1M. Notably, Coherus Oncology, Inc.'s price-to-earnings ratio is 1.06x while MediciNova, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Coherus Oncology, Inc. is 1.66x versus 296.67x for MediciNova, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHRSCoherus Oncology, Inc.1.66x 1.06x $11.6M -$44.5M MNOVMediciNova, Inc.296.67x -- $123.3K -$3.1M
-
Which has Higher Returns CHRS or VSTM?
Verastem, Inc. has a net margin of -384.73% compared to Coherus Oncology, Inc.'s net margin of -876.34%. Coherus Oncology, Inc.'s return on equity of -- beat Verastem, Inc.'s return on equity of -1773.4%.
Company Gross Margin Earnings Per Share Invested Capital CHRSCoherus Oncology, Inc.59.49% -$0.30 $142.1M VSTMVerastem, Inc.82.57% -$1.35 $74M -
What do Analysts Say About CHRS or VSTM?
Coherus Oncology, Inc. has a consensus price target of $5.67, signalling upside risk potential of 372.22%. On the other hand Verastem, Inc. has an analysts' consensus of $16.00 which suggests that it could grow by 54.44%. Given that Coherus Oncology, Inc. has higher upside potential than Verastem, Inc., analysts believe Coherus Oncology, Inc. is more attractive than Verastem, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CHRSCoherus Oncology, Inc.2 1 0 VSTMVerastem, Inc.7 0 0 -
Is CHRS or VSTM More Risky?
Coherus Oncology, Inc. has a beta of 0.951, which suggesting that the stock is 4.926% less volatile than S&P 500. In comparison Verastem, Inc. has a beta of 0.412, suggesting its less volatile than the S&P 500 by 58.798%.
-
Which is a Better Dividend Stock CHRS or VSTM?
Coherus Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Coherus Oncology, Inc. pays -- of its earnings as a dividend. Verastem, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CHRS or VSTM?
Coherus Oncology, Inc. quarterly revenues are $11.6M, which are larger than Verastem, Inc. quarterly revenues of $11.2M. Coherus Oncology, Inc.'s net income of -$44.5M is higher than Verastem, Inc.'s net income of -$98.5M. Notably, Coherus Oncology, Inc.'s price-to-earnings ratio is 1.06x while Verastem, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Coherus Oncology, Inc. is 1.66x versus 48.41x for Verastem, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHRSCoherus Oncology, Inc.1.66x 1.06x $11.6M -$44.5M VSTMVerastem, Inc.48.41x -- $11.2M -$98.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
